Veröffentlichungen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Akalin, Altuna Dr. (2) Beule, Dieter Dr. (1) Blüthgen, Nils (1) Bunse, Mario Dr. (3) Chekulaeva, Marina Dr. (1) Chen, Wei Prof. Dr. (3) Daumke, Oliver Prof. Dr. (3) Dittmar, Gunnar Dr. (1) Edes, Inan Dr. (1) Fälber, Katja Dr. (1) Franke, Vedran Dr. (2) Hammes-Lewin, Annette Dr. (1) Heinemann, Udo Prof. Dr. (1) Hirsekorn, Antje (1) Hübner, Norbert Prof. Dr. (2) Ivics, Zoltan Dr. (1) Izsvak, Zsuzsanna Dr. (2) Kammertöns, Thomas Dr. (2) Kärgel, Eva Dr. (2) Kettenmann, Helmut Prof. Dr. (1) Klußmann, Enno PD Dr. (1) Kolesnichenko, Marina Dr. (1) Ku, Min-Chi Dr. (1) Landthaler, Markus Prof. Dr. (2) Lewin, Gary Prof. Dr. (1) Lorenz, Felix Dr. (3) Lusatis, Simone (1) Mathas, Stephan Dr. (8) Meyer, Irmtraud Margret Prof. Dr. (1) Niendorf, Thoralf Prof. Dr. (1) Obermayer, Benedikt Dr. (1) Ohler, Uwe Prof. Dr. (3) Panakova, Daniela Dr. (1) Patone, Giannino Dr. (2) Poncette, Lucia (1) Rajewsky, Klaus Prof. Dr. (1) Rajewsky, Nikolaus Prof. Dr. (1) Rocks, Oliver Dr. (2) Roske, Yvette Dr. (1) Scheidereit, Claus Prof. Dr. (2) Selbach, Matthias Prof. Dr. (15) Sommer, Christian (1) Uckert, Wolfgang Prof. Dr. (12) Waiczies, Helmar Dr. (1) Waiczies, Sonia Dr. (1) Wanker, Erich Prof. Dr. (1) Woehler, Andrew Dr. (1) Wolf, Susanne Dr. (1) Wyler, Emanuel Dr. (1) Zauber, Henrik Dr. (3) Zühlke, Kerstin Dr. (1) (-) Blankenstein, Thomas Prof. Dr. (3) (-) Daniel, Peter Prof. Dr. (1) (-) Janz, Martin Dr. (5) (-) Leisegang, Matthias Dr. (3) (-) Wollert-Wulf, Brigitte (2) (-) Biologie maligner Lymphome (5) Genetik und Genomik von Herz- Kreislauferkrankungen (1) Immunregulation und Krebs (1) Molekulare Immunologie und Gentherapie (11) (-) Molekulare Zellbiologie und Gentherapie (5) Translationale Onkologie solider Tumore (1) 1998 (2) 2000 (2) 2003 (7) 2004 (3) 2005 (5) (-) 2006 (5) 2007 (3) 2008 (4) 2009 (3) 2010 (5) 2011 (6) 2012 (5) 2013 (2) 2014 (4) 2015 (5) (-) 2016 (3) 2017 (5) 2018 (1) (-) 2019 (1) 2020 (4) 2021 (3) 2022 (5) 9 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Daniel, Peter Prof. Dr.Janz, Martin Dr.Leisegang, Matthias Dr.Wollert-Wulf, BrigitteBiologie maligner LymphomeMolekulare Zellbiologie und Gentherapie200620162019 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 02. Januar 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein 01. Juni 2016 in Clin Cancer Res Eradication of large solid tumors by gene therapy with a T cell receptor targeting a single cancer-specific point mutation M. Leisegang B. Engels K. Schreiber P.Y. Yew K. Kiyotani C. Idel A. Arina J. Duraiswamy R.R. Weichselbaum W. Uckert Y. Nakamura H. Schreiber 03. Mai 2016 in Proc Natl Acad Sci U S A Canonical NF-κB signaling is uniquely required for the long-term persistence of functional mature B cells E. Derudder S. Herzog V. Labi T. Yasuda K. Köchert M. Janz A. Villunger M. Schmidt-Supprian K. Rajewsky 01. März 2016 in J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein 01. November 2006 in Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert 15. Mai 2006 in Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas 01. April 2006 in Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel 15. März 2006 in Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 01. Februar 2006 in Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
02. Januar 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein
01. Juni 2016 in Clin Cancer Res Eradication of large solid tumors by gene therapy with a T cell receptor targeting a single cancer-specific point mutation M. Leisegang B. Engels K. Schreiber P.Y. Yew K. Kiyotani C. Idel A. Arina J. Duraiswamy R.R. Weichselbaum W. Uckert Y. Nakamura H. Schreiber
03. Mai 2016 in Proc Natl Acad Sci U S A Canonical NF-κB signaling is uniquely required for the long-term persistence of functional mature B cells E. Derudder S. Herzog V. Labi T. Yasuda K. Köchert M. Janz A. Villunger M. Schmidt-Supprian K. Rajewsky
01. März 2016 in J Clin Invest Targeting human melanoma neoantigens by T cell receptor gene therapy M. Leisegang T. Kammertoens W. Uckert T. Blankenstein
01. November 2006 in Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
15. Mai 2006 in Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
01. April 2006 in Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
15. März 2006 in Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. Februar 2006 in Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
